Goldman Sachs Group, Inc. (The) set a €72.00 ($84.71) price objective on Morphosys AG (ETR:MOR) in a research report sent to investors on Wednesday, November 8th. The firm currently has a neutral rating on the stock.
Several other analysts have also recently commented on the company. Commerzbank Ag set a €76.00 ($89.41) target price on Morphosys AG and gave the stock a buy rating in a research report on Thursday, August 31st. Deutsche Bank AG set a €90.00 ($105.88) target price on Morphosys AG and gave the stock a buy rating in a research report on Thursday, September 7th. Berenberg Bank set a €68.00 ($80.00) target price on Morphosys AG and gave the stock a buy rating in a research report on Friday, July 14th. Independent Research GmbH set a €77.00 ($90.59) target price on Morphosys AG and gave the stock a buy rating in a research report on Thursday, September 7th. Finally, J P Morgan Chase & Co reaffirmed a buy rating and issued a target price on shares of Morphosys AG in a research report on Thursday, November 2nd. Two research analysts have rated the stock with a hold rating and six have given a buy rating to the stock. The stock currently has an average rating of Buy and a consensus target price of €81.25 ($95.59).
Shares of Morphosys AG (ETR:MOR) opened at €81.93 ($96.39) on Wednesday. Morphosys AG has a 12-month low of €40.10 ($47.18) and a 12-month high of €82.20 ($96.71).
Morphosys AG Company Profile
MorphoSys AG, together with its subsidiaries, engages in the research, development, and optimization of therapeutic antibody drug candidates in partnerships with pharmaceutical and biotechnology companies. The company, together with its pharmaceutical partners, develops a therapeutic pipeline of approximately 100 human antibody drug candidates for the treatment of cancer, rheumatoid arthritis, Alzheimer's disease, infectious diseases, cardiovascular dysfunction, and inflammation.
Receive News & Ratings for Morphosys AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Morphosys AG and related companies with our FREE daily email newsletter.